Ask AI
Bispecific Antibodies in MM

CE

APP Perspectives: Managing Toxicities With Bispecific Antibodies in Multiple Myeloma

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 07, 2025

Expiration: May 06, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13:116. 
  2. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495-505.
  3. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259-2267.
  4. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232-2244.
  5. Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42:2702-2712. 
  6. Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205-e216. 
  7. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. V1.2025. nccn.org. Accessed November 6, 2025.
  8. National Comprehensive Cancer Network. Management of CAR T-cell and lymphocyte engager-related toxicities. Version 1.2026. nccn.org. Accessed November 6, 2025.
  9. Chari A, Krishnan A, Rasche L, et al. Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab. Clin Lymphoma Myeloma Leuk. 2024;24:665-693.e14.
  10. Talquetamab-tgvs [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025. 
  11. Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017:508-517.
  12. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma. Version 2.2026. nccn.org. Accessed November 6, 2025.
  13. Kurtin S, Colson K, Tariman J, et al. Adherence, persistence, and treatment fatigue in multiple myeloma. J Adv Pract Oncol. 2016;7:71-77.
  14. Mohan M, Van Oekelen O, Akhtar OS, et al. Charting the course: Sequencing immunotherapy for multiple myeloma. Am Soc Clin Oncol Educ Book. 2024;44:e432204.
  15. Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665-674. 
  16. Teclistamab-cqyv [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2025. 
  17. Elranatamab-bcmm [prescribing information]. New York, New York: Pfizer Inc.; 2025.
  18. Linvoseltamab-gcp [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2025.
  19. Garfall AL, Banerjee R, Frenzel L, et al. A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. Front Oncol. 2025;15:1630146.
  20. Golmohammadi M, Raza S, Albayyadhi M, et al. Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. Blood Cancer J. 2025;15:130.
  21. Xiao X, Huang S, Chen S, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40:367. 
  22. Shah N, Aiello J, Avigan DE, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020;8:e000734. 
  23. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002-1014.
  24. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335-347.
  25. Scott SA, Roberts DL, Gupta VA, et al. Feasibility and safety of outpatient model for administration of bispecific antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clin Lymphoma Myeloma Leuk. 2025;25:656-660.
  26. Braun A, Gouni S, Pulles A, et al. Bispecific antibody use in patients with lymphoma and multiple myeloma. Am Soc Clin Oncol Educ Book. 2024;44:e433516.
  27. Donnellan W, Lin SW, Abbas J, et al. Operationalization and use of bispecific T-cell-engaging antibodies in community practices: Multidisciplinary perspectives on developing logistics and workflow for cytokine release syndrome management. J Adv Pract Oncol. 2025;[Epub ahead of print].
  28. Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32-39.
  29. Bangolo A, Amoozgar B, Mansour C, et al. Comprehensive review of early and late toxicities in car t-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel). 2025;17:282.
  30. Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14:24.
  31. Lery M, Perrot A, Ortiz-Brugués A, et al. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab. J Am Acad Dermatol. 2024;90:376-377.
  32. Rafae A, van Rhee F, Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist. 2024;29:200-212.
  33. Chari A, Bal S, Ailawadhi S, et al. Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma. Clin Lymphoma Myeloma Leuk. 2025;25:635-645.